Silver organometallic compounds for high-efficacy, cost-effective disinfection

Overview

This solution centers on organometallic complexes of silver developed as highly effective, cost-efficient biocidal agents. Silver ions are known to be toxic to microorganisms through disruption of membrane respiratory electron transport chains and interference with DNA replication. By complexing silver with organic molecules, the technology stabilizes silver ions and enables controlled, sustained release, extending antimicrobial performance over time. Because silver-based antimicrobials target multiple abiotic pathways simultaneously, bacteria have a significantly reduced ability to develop resistance, supporting long-term product viability in the marketplace.

Technical specifications

• Slow-release silver ion delivery through organic complexation, providing sustained antimicrobial activity
• Multi-pathway mechanism of action that targets membrane respiratory electron transport and DNA replication, limiting bacterial resistance development
• Validated antimicrobial performance including an average 1 log CFU/g reduction on silver-impregnated meat liner pads versus controls
• Up to 5 log microbial reduction in 24 hours demonstrated with stainless steel coupons and cups coated with a silver-zinc zeolite (2.5% w/w silver, 14% zinc)
• Residual bactericidal activity demonstrated by an alcohol-based (79%) spray with 0.005% silver iodide, achieving greater than 3 log reduction of P. aeruginosa and S. aureus in 2 hours and greater than 4 log reduction in 8 hours
• Broad-spectrum potential applicable to bacteria, viruses, and other microorganisms across multiple product formats

Technology readiness level

The technology has demonstrated proof-of-concept efficacy across multiple application formats, including impregnated food-contact materials, coated stainless steel surfaces, and alcohol-based spray formulations. Existing validation data shows meaningful log reductions against clinically relevant pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus. Future validation is planned in three progressive phases: quantitative suspension tests for initial antimicrobial screening, laboratory simulation of real-life conditions to determine effective use-dilution and contact times, and field tests or pilot studies including in-use evaluations. These phased studies will confirm performance against bacteria, viruses, and other target microorganisms.